Second approvable letter for GSK and Pozen migraine treatment

Share this article:

The FDA delivered a further setback to GlaxoSmithKline and Pozen's developmental migraine treatment Trexima yesterday in the form of a second approvable letter seeking more data related to the drug.

Both companies said the FDA asked Pozen to address potential implications from a preclinical study into chromosomal risks in which genotoxicity was seen for the combination of naproxen sodium and sumatriptan, but not with either component alone.

Trexima combines GSK's migraine drug Imitrex (sumatriptan) with the generic anti-inflammatory, naproxen sodium.

The companies said they plan to request a meeting with the FDA as quickly as possible to discuss necessary steps to address the agency's concerns.

In June 2006, the FDA also issued an approvable letter on Trexima that asked for additional drug safety information. The FDA did not accept the drugmakers' additional data submitted by the company in November. The companies then filed additional safety data in January.

Imitrex currently holds around 56% of the migraine drug market and brought in $1.1 billion in sales for GlaxoSmithKline in 2005. With Trexima, GSK and Pozen hope to replace Imitrex as the top migraine treatment when the drug's patent expires in 2009.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...